Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS

Capital Fund Management S.A. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 46.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,219 shares of the company’s stock after selling 26,795 shares during the quarter. Capital Fund Management S.A.’s holdings in Ionis Pharmaceuticals were worth $1,233,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Allworth Financial LP boosted its holdings in Ionis Pharmaceuticals by 231.8% in the 2nd quarter. Allworth Financial LP now owns 740 shares of the company’s stock valued at $29,000 after purchasing an additional 517 shares during the period. Parallel Advisors LLC raised its position in shares of Ionis Pharmaceuticals by 151.3% in the second quarter. Parallel Advisors LLC now owns 1,872 shares of the company’s stock valued at $74,000 after buying an additional 1,127 shares in the last quarter. Ancora Advisors LLC acquired a new stake in shares of Ionis Pharmaceuticals in the first quarter valued at approximately $60,000. Signaturefd LLC boosted its stake in shares of Ionis Pharmaceuticals by 46.9% in the second quarter. Signaturefd LLC now owns 2,030 shares of the company’s stock valued at $80,000 after buying an additional 648 shares during the period. Finally, Allianz SE acquired a new stake in Ionis Pharmaceuticals during the second quarter worth approximately $83,000. 93.86% of the stock is owned by institutional investors.

Analysts Set New Price Targets

IONS has been the subject of several analyst reports. BMO Capital Markets raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $40.00 to $70.00 in a report on Wednesday, September 3rd. Wall Street Zen downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Guggenheim upped their price objective on shares of Ionis Pharmaceuticals from $90.00 to $92.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. Stifel Nicolaus raised their target price on shares of Ionis Pharmaceuticals from $43.00 to $67.00 and gave the company a “hold” rating in a report on Monday, October 6th. Finally, Cowen restated a “buy” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.15.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Joseph H. Wender sold 28,000 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $80.82, for a total value of $2,262,960.00. Following the completion of the transaction, the director owned 36,035 shares of the company’s stock, valued at $2,912,348.70. This represents a 43.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Shannon L. Devers sold 16,777 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $80.91, for a total value of $1,357,427.07. Following the completion of the transaction, the executive vice president owned 17,494 shares of the company’s stock, valued at $1,415,439.54. This represents a 48.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 527,566 shares of company stock valued at $37,210,312. 2.60% of the stock is owned by company insiders.

Ionis Pharmaceuticals Stock Down 0.0%

IONS stock opened at $81.81 on Friday. The firm has a 50-day moving average price of $73.24 and a 200-day moving average price of $54.08. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $83.61. The company has a current ratio of 2.79, a quick ratio of 2.78 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $13.25 billion, a P/E ratio of -48.41 and a beta of 0.30.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.35. The business had revenue of $156.72 million during the quarter, compared to analysts’ expectations of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.95) EPS. As a group, equities research analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.